Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review

Research output: Contribution to journalReviewResearchpeer-review

  1. Checkpoint inhibitors in pancreatic cancer

    Research output: Contribution to journalReviewResearchpeer-review

  2. Checkpoint inhibitors in breast cancer - Current status

    Research output: Contribution to journalReviewResearchpeer-review

  3. A systematic review of bevacizumab efficacy in breast cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: Despite advances in the treatment of colorectal cancer, third-line treatment options are still limited. Regorafenib was approved in 2012 for the treatment of patients with metastatic colorectal cancer previously treated with approved standard therapy. The purpose of this review is to present existing clinical data on regorafenib.

METHOD: We systematically searched the PubMed and Embase databases, as well as ASCO and ESMO conference abstracts, for studies in English including ≥30 patients, evaluating the efficacy and safety of regorafenib in patients with metastatic colorectal cancer. A meta-analysis was conducted on the published, randomized phase III trials.

RESULTS: 24 eligible studies were included. In two phase III trials, regorafenib significantly increased overall survival (OS), progression free survival (PFS), and disease control rate when compared to placebo. Survival benefits of 1.4 and 2.5 months were presented. The meta-analysis indicated a significant greater treatment effect on OS (hazard ratio 0.67) and PFS (hazard ratio 0.40), compared to placebo. The non-randomized studies mostly supported these results. The most frequently reported adverse events were hand-foot-skin reaction (25%-86%), hypertension (11%-47%) and fatigue (2%-73%).

CONCLUSION: Large phase III randomized trials indicate that regorafenib provides a benefit in OS and PFS when compared to placebo. Adverse events were common, but manageable and typical of multi-target tyrosine kinase inhibitors. Further research is needed to investigate alternative approaches to the dosing of regorafenib and to explore clinical and molecular biomarkers that can guide patient selection.

Original languageEnglish
JournalCancer Treatment Reviews
Volume62
Pages (from-to)61-73
Number of pages13
ISSN0305-7372
DOIs
Publication statusPublished - Jan 2018

    Research areas

  • Antineoplastic Agents/therapeutic use, Clinical Trials, Phase III as Topic, Colorectal Neoplasms/drug therapy, Disease-Free Survival, Fatigue/chemically induced, Hand-Foot Syndrome/etiology, Humans, Hypertension/chemically induced, Neoplasm Metastasis, Phenylurea Compounds/therapeutic use, Proportional Hazards Models, Pyridines/therapeutic use, Survival Rate

ID: 56562560